Abbott Laboratories' stock plummeted 10.92% during Thursday's intraday trading session, following the release of its fourth-quarter 2025 financial results and 2026 outlook that disappointed investors.

The healthcare products maker reported Q4 revenue of $11.46 billion, missing the consensus estimate of $11.80 billion. The revenue shortfall was driven by continued weakness in the company's diagnostics business, which saw a 2.5% decline due to lower COVID-19 testing demand, and a significant 8.9% drop in its nutrition segment.

Adding to investor concerns, Abbott issued first-quarter 2026 adjusted EPS guidance of $1.12-$1.18, which fell below the $1.20 analyst estimate. While the company's full-year adjusted EPS outlook of $5.55-$5.80 was around expectations, the combination of the revenue miss and soft near-term guidance led to the sharp selloff.